Overview

* Rigel Q2 2025 revenue of $101.7 mln beats analyst expectations, per LSEG data

* Company reports Q2 net income of $59.6 mln, reversing a loss from last year

* Net product sales grew 76% yr/yr, driven by TAVALISSE and GAVRETO

Outlook

* Rigel updates 2025 revenue guidance to $270-$280 mln

* Company expects net product sales of $210-$220 mln in 2025

* Rigel forecasts $60 mln in contract revenues from collaborations

* Company anticipates positive net income for full-year 2025

Result Drivers

* NET PRODUCT SALES - Rigel's net product sales increased by 76% year-over-year, driven by TAVALISSE and GAVRETO

* NON-CASH REVENUE - Recognized $40 mln in non-cash revenue from agreement with Eli Lilly, contributing to contract revenues

* INTERNATIONAL EXPANSION - Launch of TAVALISSE in South Korea by partner Kissei contributed to sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $101.70 $88.90

Revenue mln mln (3

Analysts

)

Q2 EPS $3.28

Q2 Net $59.6

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc ( RIGL ) is $23.50, about 3.5% above its August 4 closing price of $22.67

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)